Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway.

Clin Transl Immunology · 2016 · PMC4910120 · PMID 27350879

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

22 Trials of atacicept, which blocks the activity of two B-cell survival factors, BAFF and APRIL were terminated prematurely in phase II/III due to safety concerns; however, the data showed a trend to benefit for the higher dose tested. 23 Studies of B cell-directed agents continue, with modifications to improve efficacy, such as obinutuzumab, an anti-CD20 mAb engineered for enhanced cytotoxicity ( NCT02550652 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.